Baldwin Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Baldwin Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.89M	Hold	7,824	–	–	0.25%	66
2026 Q1	$3.49M	Hold	7,824	–	–	0.25%	64
2025 Q4	$3.55M	Sell	7,824 -120	-2%	-$51.7K	0.23%	65
2025 Q3	$3.11M	Sell	7,944 -50	-0.6%	-$20.9K	0.2%	71
2025 Q2	$3.56M	Sell	7,994 -125	-2%	-$57.6K	0.24%	66
2025 Q1	$3.94M	Sell	8,119 -878	-10%	-$409K	0.28%	62
2024 Q4	$3.62M	Hold	8,997	–	–	0.25%	67
2024 Q3	$4.18M	Buy	8,997 +11	+0.1%	+$5.28K	0.29%	65
2024 Q2	$4.21M	Buy	8,986 +4	+0%	+$1.74K	0.33%	62
2024 Q1	$3.75M	Sell	8,982 -190	-2%	-$80.3K	0.28%	66
2023 Q4	$3.73M	Buy	9,172 +35	+0.4%	+$12.9K	0.29%	66
2023 Q3	$3.18M	Sell	9,137 -250	-3%	-$87.4K	0.27%	71
2023 Q2	$3.3M	Hold	9,387	–	–	0.27%	75
2023 Q1	$2.96M	Hold	9,387	–	–	0.26%	78
2022 Q4	$2.71M	Buy	9,387 +9,312	+12,416%	+$2.84M	0.25%	85
2022 Q3	$22K	Hold	75	–	–	﹤0.01%	439
2022 Q2	$21K	Hold	75	–	–	﹤0.01%	469
2022 Q1	$20K	Hold	75	–	–	﹤0.01%	479
2021 Q4	$16K	Hold	75	–	–	﹤0.01%	466
2021 Q3	$14K	Hold	75	–	–	﹤0.01%	489
2021 Q2	$15K	Hold	75	–	–	﹤0.01%	495
2021 Q1	$16K	Hold	75	–	–	﹤0.01%	482
2020 Q4	$18K	Hold	75	–	–	﹤0.01%	413
2020 Q3	$20K	Hold	75	–	–	﹤0.01%	388
2020 Q2	$22K	Hold	75	–	–	﹤0.01%	383
2020 Q1	$18K	Hold	75	–	–	﹤0.01%	386
2019 Q4	$16K	Sell	75 -4	-5%	-$810	﹤0.01%	425
2019 Q3	$14K	Sell	79 -918	-92%	-$162K	﹤0.01%	433
2019 Q2	$183K	Sell	997 -226	-18%	-$39.5K	0.03%	205
2019 Q1	$225K	Hold	1,223	–	–	0.03%	192
2018 Q4	$202K	Hold	1,223	–	–	0.03%	189
2018 Q3	$235K	Sell	1,223 -81	-6%	-$14.4K	0.03%	191
2018 Q2	$222K	Hold	1,304	–	–	0.03%	186
2018 Q1	$213K	Buy	1,304 +75	+6%	+$12.3K	0.03%	188
2017 Q4	$184K	Buy	+1,229	New	+$182K	0.03%	202
2016 Q2	–	Sell	-1,000	Closed	-$79K	–	496
2016 Q1	$79K	Buy	+1,000	New	+$90.5K	0.01%	262

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Baldwin Wealth Partners's VRTX Position: Q2 2026 in Review

Baldwin Wealth Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 7,824 shares worth $3.89M. The position accounts for 0.25% of the portfolio, ranked #66.

Baldwin Wealth Partners first reported a position in VRTX in Q1 2016 and has held it in 36 quarters since. The position peaked at $4.21M in Q2 2024. 301 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Baldwin Wealth Partners held 7,824 shares of Vertex Pharmaceuticals worth $3.89M as of Q2 2026.
Baldwin Wealth Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.25% of Baldwin Wealth Partners's portfolio in Q2 2026, its #66 holding.
Baldwin Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 36 quarters since.
Baldwin Wealth Partners's Vertex Pharmaceuticals position peaked at $4.21M in Q2 2024.
301 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Baldwin Wealth Partners's 13F filing for Q2 2026, filed 14 Jul 2026.